Unfortunately, the majority of patients inevitably acquire resistance after several cycles of treatment [2, 3]; therefore, it is crucial to actively explore the mechanisms of anti-PD1 resistance in NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.